AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30474592 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model for outcome 2 (same symptoms as outcome 1 plus recurrence of injury)
Number of subjects: 1266
Study 30474592 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated models with additional variable (pain when bearing weight on the ankle) at 4 weeks post injury
Number of subjects: 1266
Study 30474592 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of outcome 1 model
Number of subjects: 1266
Study 30474592 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of outcome 2 model
Number of subjects: 1266
Study 27563670 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga training (8 weeks, 2 times/week, total of 16 sessions)
Number of subjects: 30
Study 27563670 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga training
Number of subjects: 30
Study 24363238 — intervention group
Group type: COMPARATOR
Intervention: Frovatriptan 2.5 mg alone (Frova)
Number of subjects: 314
Study 24363238 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg + dexketoprofen 25 mg (FroDex25)
Number of subjects: 314
Study 24363238 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg + dexketoprofen 37.5 mg (FroDex37.5)
Number of subjects: 314
Study 22205619 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed pleural drainage using a central venous catheter (CVC)
Number of subjects: 407
Study 22205619 — intervention group
Group type: COMPARATOR
Intervention: Conventional chest tube
Number of subjects: 407
Study 19915475 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 167
Study 19915475 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (pLMA)
Number of subjects: 167
Study 19915475 — intervention group
Group type: COMPARATOR
Intervention: classic laryngeal mask airway (cLMA)
Number of subjects: 167
Study 19915475 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel, pLMA, cLMA
Number of subjects: 167
Study 19915475 — intervention group
Group type: COMPARATOR
Intervention: cLMA
Number of subjects: 167
Study 18729683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 61
Study 18729683 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 61
Study 16059992 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg/12 h infusion followed by 1200 mg/24 h orally) and Vitamin E (600 mg/24 h)
Number of subjects: 800
Study 16059992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 12444833 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visitation program
Number of subjects: 232
Study 12444833 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 232
Study 10411934 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-2147
Number of subjects: 7
Study 10411934 — intervention group
Group type: COMPARATOR
Intervention: KNI-272
Number of subjects: 7
Study 8873488 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (comprehensive patient education, dietary and social service consultations, medication review, intensive postdischarge follow‐up)
Number of subjects: 156
Study 8873488 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 156
Study 8873488 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Number of subjects: 156
Study 1387607 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg/day for one week
Number of subjects: 10
Study 1387607 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose adrenaline infusion
Number of subjects: 10
Study 1387607 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP in vitro
Number of subjects: 10
Study 1387607 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 10
Study 6469443 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg buflomedil
Number of subjects: 10
Study 6469443 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg buflomedil
Number of subjects: 10
Study 6469443 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg buflomedil
Number of subjects: 10
Study 6469443 — intervention group
Group type: COMPARATOR
Intervention: 2000 mg piracetam
Number of subjects: 10
Study 6469443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29577550 — intervention group
Group type: COMPARATOR
Intervention: ZGN-1061 (SAD phase, N=28)
Number of subjects: 39
Study 29577550 — intervention group
Group type: COMPARATOR
Intervention: ZGN-1061 (MAD phase, N=22)
Number of subjects: 39
Study 29577550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SAD phase, N=11)
Number of subjects: 39
Study 29577550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (MAD phase, N=7)
Number of subjects: 39
Study 26602363 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of lifestyle intervention (IIG)
Number of subjects: 62
Study 26602363 — intervention group
Group type: COMPARATOR
Intervention: Delayed start control group (DSCG)
Number of subjects: 62
Study 26602363 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after 3 months of intensive intervention
Number of subjects: 62
Study 25408736 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 70
Study 25408736 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical activity intervention)
Number of subjects: 70
Study 22116296 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive Masimo Hb (SpHb) measurement
Number of subjects: 50
Study 21179732 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild warming moxibustion (MWM) on acupoints Shenque (RN8) and Guanyuan (RN4) for 3 months
Number of subjects: 64
Study 21179732 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dripping of immunoglobulin for 3 months (Control)
Number of subjects: 64
Study 21179732 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 17570902 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA (risperidone or clozapine)
Number of subjects: 18
Study 17570902 — intervention group
Group type: COMPARATOR
Intervention: FGA
Number of subjects: 18
Study 16188898 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐flux cuprammonium (CU) dialyser
Number of subjects: 15
Study 16188898 — intervention group
Group type: EXPERIMENTAL
Intervention: All dialyser modalities
Number of subjects: 15
Study 16188898 — intervention group
Group type: COMPARATOR
Intervention: Baseline levels in chronic HD patients
Number of subjects: 15
Study 11870387 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a (40 kd)
Number of subjects: 1441
Study 11870387 — intervention group
Group type: COMPARATOR
Intervention: interferon alfa‐2a
Number of subjects: 1441
Study 12016811 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIgG (100‐300 mg.kg‐1.d‐1) for 2‐3 days
Number of subjects: 54
Study 12016811 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 54
Study 7570325 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic herniorrhaphy (LH)
Number of subjects: 0
Study 7570325 — intervention group
Group type: COMPARATOR
Intervention: Open hernia repair (OH)
Number of subjects: 0
Study 1705274 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day tamoxifen
Number of subjects: 38
Study 1705274 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 38
Study 7349450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton pad impregnated with diverse secretions of the mother
Number of subjects: 0
Study 7349450 — intervention group
Group type: COMPARATOR
Intervention: Cotton pad impregnated with secretions of another mother or a pad with no specific odour
Number of subjects: 0
Study 7349450 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory recognition by mothers of their baby's odour
Number of subjects: 0
Study 7349450 — intervention group
Group type: EXPERIMENTAL
Intervention: Tee-shirt worn against the mother's skin for 2 to 3 days
Number of subjects: 0
Study 31116114 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 10 cmH2O
Number of subjects: 30
Study 31116114 — intervention group
Group type: COMPARATOR
Intervention: ZEEP
Number of subjects: 30
Study 31116114 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-oxygenation with CPAP 10 cmH2O
Number of subjects: 30
Study 31116114 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of oesophageal sphincter pressures pre-oxygenation vs after anaesthesia induction
Number of subjects: 30
Study 27029939 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cost home‐based virtual reality system for rehabilitation of the arm (8 weeks use)
Number of subjects: 27
Study 27029939 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 27
Study 25908106 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 148
Study 25908106 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without comorbid anxiety)
Number of subjects: 148
Study 23411616 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (n=602)
Number of subjects: 1145
Study 23411616 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy without candesartan (n=543)
Number of subjects: 1145
Study 20094823 — intervention group
Group type: COMPARATOR
Intervention: Exhaled carbon monoxide (eCO) levels in asthmatic patients
Number of subjects: 19
Study 20094823 — intervention group
Group type: COMPARATOR
Intervention: Exhaled carbon monoxide (eCO) levels in allergic rhinitis patients
Number of subjects: 19
Study 20094823 — intervention group
Group type: COMPARATOR
Intervention: HO-1 expression in asthmatic patients
Number of subjects: 19
Study 20094823 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy in asthmatic patients
Number of subjects: 19
Study 19232940 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of ephedrine per 20 mL of propofol (Group E15)
Number of subjects: 156
Study 19232940 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of ephedrine per 20 mL of propofol (Group E30)
Number of subjects: 156
Study 19232940 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine per 20 mL of 1% propofol (Group L)
Number of subjects: 156
Study 17446700 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate-based CVVH
Number of subjects: 30
Study 17446700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin-based CVVH
Number of subjects: 30
Study 17446700 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 15385385 — intervention group
Group type: EXPERIMENTAL
Intervention: endotracheal lidocaine 160 mg
Number of subjects: 50
Study 15385385 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 11427213 — intervention group
Group type: EXPERIMENTAL
Intervention: avasimibe 50 mg
Number of subjects: 130
Study 11427213 — intervention group
Group type: EXPERIMENTAL
Intervention: avasimibe 125 mg
Number of subjects: 130
Study 11427213 — intervention group
Group type: EXPERIMENTAL
Intervention: avasimibe 250 mg
Number of subjects: 130
Study 11427213 — intervention group
Group type: EXPERIMENTAL
Intervention: avasimibe 500 mg
Number of subjects: 130
Study 11427213 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 130
Study 9700115 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach educational program
Number of subjects: 20
Study 9700115 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 9441080 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (SCC) regimen
Number of subjects: 33
Study 9441080 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus chemotherapy
Number of subjects: 33
Study 9441080 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 33
Study 2008945 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (2 MAC in 100% oxygen)
Number of subjects: 100
Study 2008945 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (2 MAC in 100% oxygen)
Number of subjects: 100
Study 2008945 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (extubation after awakening)
Number of subjects: 100
Study 2008945 — intervention group
Group type: COMPARATOR
Intervention: Halothane (extubation after awakening)
Number of subjects: 100
Study 2008945 — intervention group
Group type: COMPARATOR
Intervention: Awake extubation (either agent)
Number of subjects: 100
Study 6812143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-tryptophan (TRP)
Number of subjects: 10
Study 6812143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31371212 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT) plus placebo
Number of subjects: 153
Study 31371212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) plus fluoxetine (20 mg daily)
Number of subjects: 153
Study 28346003 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% diclofenac sodium cream applied topically every 12 hours for 7 days
Number of subjects: 12
Study 28346003 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied topically every 12 hours for 7 days
Number of subjects: 12
Study 26341769 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical subinguinal varicocelectomy with testicular delivery (group 1)
Number of subjects: 100
Study 26341769 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical subinguinal varicocelectomy without testicular delivery (group 2)
Number of subjects: 100
Study 24613047 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 21
Study 24613047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 22584619 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-row technique
Number of subjects: 160
Study 22584619 — intervention group
Group type: COMPARATOR
Intervention: Single-row technique
Number of subjects: 160
Study 18667807 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training
Number of subjects: 20
Study 18667807 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 17141859 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol (400/12 mug)
Number of subjects: 15
Study 17141859 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 mug)
Number of subjects: 15
Study 17141859 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 mug)
Number of subjects: 15
Study 17141859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17141859 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Budesonide/Formoterol, Formoterol, Budesonide)
Number of subjects: 15
Study 15367427 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion with a target dose of 0.5 x 10(11)/10 kg (arm A)
Number of subjects: 101
Study 15367427 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion with a target dose of 1 x 10(11)/10 kg (arm B)
Number of subjects: 101
Study 12538121 — intervention group
Group type: EXPERIMENTAL
Intervention: Allon thermoregulatory (AT) system
Number of subjects: 60
Study 12538121 — intervention group
Group type: COMPARATOR
Intervention: Routine thermal care (RTC)
Number of subjects: 60
Study 9322459 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanolone (0.75 mg/kg i.v. for 18-60 yr or ASA I/II; 0.5 mg/kg i.v. for 61-80 yr or ASA III)
Number of subjects: 83
Study 9322459 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanolone (1.0 mg/kg i.v. for 18-60 yr or ASA I/II; 0.75 mg/kg i.v. for 61-80 yr or ASA III)
Number of subjects: 83
Study 9322459 — intervention group
Group type: COMPARATOR
Intervention: Propofol (2.4 mg/kg i.v. for 18-60 yr or ASA I/II; 1.6 mg/kg i.v. for 61-80 yr or ASA III)
Number of subjects: 83
Study 8229121 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention group receiving a program of individualized instruction for reducing total fat intake
Number of subjects: 290
Study 8229121 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention group
Number of subjects: 290
Study 8229121 — intervention group
Group type: COMPARATOR
Intervention: Dietary control group with minimal dietary counseling
Number of subjects: 290
Study 3753924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 25 mg
Number of subjects: 12
Study 3753924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg
Number of subjects: 12
Study 3753924 — intervention group
Group type: COMPARATOR
Intervention: Propantheline 30 mg
Number of subjects: 12
Study 3753924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30036739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bevacizumab, oxaliplatin and fluoropyrimidine
Number of subjects: 754
Study 24977690 — intervention group
Group type: EXPERIMENTAL
Intervention: AEG35156 (300 mg weekly intravenous infusion) in combination with sorafenib (400 mg twice daily orally)
Number of subjects: 51
Study 24977690 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib alone (400 mg twice daily orally)
Number of subjects: 51
Study 23995295 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples HIV testing and counseling (CHTC)
Number of subjects: 0
Study 23995295 — intervention group
Group type: COMPARATOR
Intervention: Individual voluntary HIV counseling and testing (iVCT)
Number of subjects: 0
Study 22187070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 1380
Study 22187070 — intervention group
Group type: COMPARATOR
Intervention: Regular colonoscopy (CC)
Number of subjects: 1380
Study 20620323 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal endorectal pull-through (TERP)
Number of subjects: 281
Study 20620323 — intervention group
Group type: COMPARATOR
Intervention: Transabdominal approach (TAA)
Number of subjects: 281
Study 18552687 — intervention group
Group type: COMPARATOR
Intervention: Protocolized Sedation (PS)
Number of subjects: 65
Study 18552687 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized Sedation + Daily Interruption (PS + DI)
Number of subjects: 65
Study 18552687 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PS and PS + DI)
Number of subjects: 65
Study 16002965 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum Induction (SI)
Number of subjects: 13
Study 16002965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar Lavage (BAL)
Number of subjects: 13
Study 16002965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (O(3)) exposure
Number of subjects: 13
Study 16002965 — intervention group
Group type: COMPARATOR
Intervention: Filtered Air (FA) exposure
Number of subjects: 13
Study 12218525 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexmedetomidine (target plasma concentration 0.3 ng/ml)
Number of subjects: 0
Study 12218525 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexmedetomidine (target plasma concentration 0.6 ng/ml)
Number of subjects: 0
Study 12218525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12218525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (both doses) during shivering
Number of subjects: 0
Study 10507599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine 0.5 microg/kg/min
Number of subjects: 38
Study 10507599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine 2.0 microg/kg/min
Number of subjects: 38
Study 10507599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 8725976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol Treatment Program (CTP)
Number of subjects: 247
Study 8725976 — intervention group
Group type: COMPARATOR
Intervention: Usual Health Care (UHC)
Number of subjects: 247
Study 1890156 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (20 mg)
Number of subjects: 0
Study 1890156 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (40 mg)
Number of subjects: 0
Study 1890156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6731022 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 39
Study 6731022 — intervention group
Group type: COMPARATOR
Intervention: Metrizoate
Number of subjects: 39
Study 31099992 — intervention group
Group type: EXPERIMENTAL
Intervention: RD3 (dexmedetomidine at an initial dose of 0.5 μg/kg for 10 min adjusted to 0.6 μg kg−1 hr−1 throughout EIT)
Number of subjects: 86
Study 31099992 — intervention group
Group type: COMPARATOR
Intervention: Control group (sufentanil only)
Number of subjects: 86
Study 29042172 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised upper limb program (SULP)
Number of subjects: 80
Study 29042172 — intervention group
Group type: COMPARATOR
Intervention: No supervised upper limb program (NULP)
Number of subjects: 80
Study 26689231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactobacillus casei strain Shirota (LcS), consumed once a day for 8 weeks
Number of subjects: 47
Study 26689231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactobacillus casei strain Shirota (LcS)
Number of subjects: 47
Study 26689231 — intervention group
Group type: COMPARATOR
Intervention: Placebo milk, consumed once a day for 8 weeks
Number of subjects: 47
Study 25193490 — intervention group
Group type: EXPERIMENTAL
Intervention: Video administered at one month (early intervention)
Number of subjects: 105
Study 25193490 — intervention group
Group type: EXPERIMENTAL
Intervention: Video administered at seven months (late intervention)
Number of subjects: 105
Study 25193490 — intervention group
Group type: COMPARATOR
Intervention: Both early and late intervention groups
Number of subjects: 105
Study 22927525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 250 mg/m(2)
Number of subjects: 39
Study 22927525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 250 mg/m(2) with paclitaxel 80 mg/m(2)
Number of subjects: 39
Study 20496732 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Baihui (GV 20) and Zusanli (ST 36)
Number of subjects: 84
Study 20496732 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture at Taichong (LR 3), Sanyinjiao (SP 6), Neiguan (PC 6), and Shenmen (HT 7)
Number of subjects: 84